

THE AM LAW LITIGATION DAILY

Litigator of the Week Runners-Up and Shout-Outs

By Ross Todd

October 9, 2026

➤ Staying in the Janssen Biotech litigation universe, a patent litigation team at **Latham & Watkins** secured an injunction for the company blocking the launch of its biosimilar version of the company's blockbuster autoimmune treatments Simponi and Simponi Aria. Last week, U.S. District Judge Gregory B. Williams of the District of Delaware granted Janssen's motion for a preliminary injunction, barring Accord BioPharma and Bio-Thera Solutions from commercially manufacturing, selling or importing their biosimilar, BAT2506, in the United States. My colleagues at IAM report that the preliminary injunction was just the fifth awarded in 12 years of litigation under the Biologics Price Competition and Innovation Act. The Latham team included partners **Roger Chin, David Frazier, Mike Morin**, and **Michael Seringhaus** and associates **Cecilia Bain, Chaaru Deb, Peter Hoffman, Sarah Propst, Drew Roberts, Ramya Vallabhaneni** and **Kevin Zhang**, with co-counsel Daniel Silver and Alexandra Joyce of McCarter & English.

➤ Shout-out to **Blake Denton, Colleen Smith** and a **Latham & Watkins** team that secured a first-pass dismissal with prejudice of a securities class action against electric-vehicle maker VinFast after its stock had fallen from a post-listing high of about \$81 to \$2.43. Plaintiffs pointed to a whistleblower and a federal safety investigation, but U.S. District Judge Nicholas Garaufis in Brooklyn found their allegations failed to state their securities claims and ordered the cases closed. Denton argued the motion to dismiss. The Latham team included associates **Ashley Gebicke, Sandra Scott, Rose-Marie Jung** and **Brian Henson**.